What Fycompa treats: main uses and benefits

Fycompa is commonly used for managing certain types of seizures in patients with epilepsy and is applied in addressing symptoms related to heightened physiological activity. It is generally applied across domains where additional symptomatic support is needed. It is relevant in clinical settings as a single therapy or as part of a combination regimen for conditions involving Focal-Onset Seizures (FOS) and Primary Generalized Tonic-Clonic Seizures (PGTCS).

This medication addresses symptom clusters that create noticeable physiological strain, particularly those involving recurrent convulsions and symptoms associated with acute or episodic changes. It is used in situations involving difficult-to-manage, or drug-resistant, epilepsy. A key benefit involves offering symptomatic relief that helps patients cope more steadily with difficult episodes and may assist with reducing the frequency of symptoms when they become difficult to tolerate.

Therapeutic Focus: Managing Convulsive Symptoms
Common Use: Used across conditions presenting with acute episodes of focal or generalized tonic-clonic seizure manifestations.
Symptom Focus: Helps address symptom clusters that may become intense or disruptive, including symptoms that interfere with daily functioning.
Patient Benefit: Provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort.

Who can and cannot use Файкомпа (Perampanel)?

Eligibility for Файкомпа is strictly determined by official regulatory documents, defining age, seizure type, and specific health restrictions.

Population Eligibility and Restrictions

Category	Regulatory Status
Partial-Onset Seizures (POS)	Approved for patients 4 years of age and older.
Primary Generalized Tonic-Clonic Seizures (PGTCS)	Approved for patients 12 years of age and older (US) or 7 years and older (EU).
Hypersensitivity	Use is contraindicated in patients with a known hypersensitivity to perampanel or its components (EU labeling).
Severe Organ Impairment	Use is not recommended in patients with severe hepatic impairment or severe renal impairment / hemodialysis.
Moderate Organ Impairment	Use is restricted in moderate hepatic impairment, with a mandated limit on the maximum dose.
Pregnancy and Lactation	Use is restricted due to lack of adequate human data; breastfeeding is not recommended during treatment.

Eligibility is only established for the approved age groups and seizure types, and is subject to mandatory exclusion or conditional use based on the patient's existing health status, particularly liver and kidney function, as documented by official government authorities.

Interactions with other medicines and products

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Antiepileptic Drugs (AEDs) that are CYP3A inducers; Levonorgestrel-containing hormonal contraceptives; Other Central Nervous System (CNS) depressants.
Specific interacting medicines (if explicitly listed):	Carbamazepine, Phenytoin, Oxcarbazepine, Rifampin, Levonorgestrel (in contraceptives), St. John's wort (herbal product).
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic induction of CYP3A (leading to reduced Perampanel exposure). Pharmacokinetic reduction of levonorgestrel exposure. Pharmacodynamic addition of CNS depressant effects.
Timing-based interaction rules (if applicable):	No mandatory time-separation rules (e.g., "administer X hours apart") are explicitly documented.
Population-specific interaction notes (if applicable):	Use is not recommended in patients with severe hepatic impairment or severe renal impairment.
Interaction-related restrictions:	Co-use with alcohol (ethanol) is restricted due to heightened CNS depression. Co-administration with the herbal product St. John's wort is expected to reduce Perampanel plasma concentrations.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Documentation
Interaction severity classification (as defined in official documents):	Clinically significant pharmacokinetic interaction (AED inducers reduce Perampanel levels). Clinically significant pharmacokinetic interaction (Perampanel reduces Levonorgestrel levels).
Regulatory basis (EMA / FDA / etc.):	FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC), Health Canada Product Monograph.
Interaction-context constraints (as defined in official documents):	The time interval for dose adjustment must be shortened when concomitant enzyme-inducing AEDs are used.

---

Resulting Interaction Structure

Official Interaction Statements:

• Co-administration with enzyme-inducing AEDs (Carbamazepine, Phenytoin, Oxcarbazepine) increases the clearance of perampanel, leading to a significant decrease in perampanel plasma concentration.
• Perampanel at the 12 mg/day dose reduces the exposure of levonorgestrel, which may compromise the effectiveness of hormonal contraceptives.
• Concomitant use with alcohol (ethanol) or other CNS depressants has a documented additive effect on central nervous system depression.
• Use is officially not recommended in patients with severe hepatic or severe renal impairment due to potential for altered clearance.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents establish an interaction profile defined by its susceptibility to CYP3A induction, which significantly accelerates Perampanel clearance and reduces systemic exposure. This pharmacokinetic pattern necessitates constraints when co-administered with inducing medicines. An important restriction is the reduction in exposure of levonorgestrel, formally documented as a clinically relevant interaction that compromises hormonal contraceptive effectiveness. The interaction profile is completed by the official note on the additive CNS depressant effects observed when Perampanel is combined with alcohol or other depressants.

Targeting Excitatory Neurotransmission

Файкомпа (Perampanel) functions as a selective, non-competitive antagonist of the AMPA glutamate receptor within the central nervous system. The drug acts within domains involving receptor-mediated signaling to modulate processes driven by excitatory signaling patterns. This interaction occurs specifically at postsynaptic sites, where it interferes with the binding and action of the neurotransmitter glutamate.

---

Modulating Postsynaptic Activity

By occupying a site distinct from the glutamate binding pocket, Файкомпа modifies early molecular steps that shape systemic physiological outcomes by blocking the current flow mediated by AMPA receptor activation. This inhibition of the primary excitatory pathway is relevant in systems where excessive glutamate activity dominates, resulting in a reduction of excessive mediator activity within the neuronal microenvironment.

---

Downstream Pathway Regulation

The core mechanistic cascade involves a targeted pathway adjustment that influences internal feedback regulation. Dampening the primary excitatory current mediated by the AMPA receptor establishes a modified, regulated state of neuronal excitability. This systemic physiological adjustment defines the drug's overall pharmacodynamic effect profile.

How to use Файкомпа — Administration Guidelines

The administration of perampanel follows a structured dose-titration protocol designed for long-term oral use. The medication is taken by the oral route, utilizing either film-coated tablets or an oral suspension.

---

Administration Element	Instruction
Frequency and Timing	The dose is taken once daily at bedtime.
Standard Dosing Schedule	Treatment is initiated at a starting dose of 2 mg once daily. The dose is then increased gradually by 2 mg increments no more frequently than at weekly intervals until the required stable dose is achieved. The maximum dose is 12 mg daily.
Intake Condition	The dose may be taken with or without food, but guidelines suggest administering it under the same circumstances each day for consistency.
Preparation Rules	Tablets must be swallowed whole with water and should not be crushed, chewed, or split. The oral suspension must be shaken well and measured with the dedicated dosing syringe.
Population Adjustment	The titration period is typically extended to no more frequently than every two weeks for elderly patients or those with mild to moderate hepatic impairment. A different starting dose (e.g., 4 mg) may be used when the patient is concurrently taking certain other seizure medications.

---

This standardized, dose-escalation protocol defines a long-term treatment plan characterized by an initial titration phase followed by a stable maintenance phase. The practice of taking the single daily dose at bedtime establishes a consistent schedule for maintaining the drug's intended usage structure.

Research evidence / Overview of studies for Файкомпа

Evidence for Focal-Onset Seizures

The evidence base for Файкомпа (Perampanel) for focal-onset seizures (FOS) includes a substantial body of research. This area was first evaluated in multiple Phase III Randomized Controlled Trials (RCTs). These short-term, controlled studies compared the medicine against a placebo, primarily in adults and adolescents with drug-resistant epilepsy. Researchers monitored outcomes related to episodic or acute changes, such as seizure frequency and the 50% responder rate.

Findings described in these RCTs and supporting meta-analyses highlight patterns measured during the study period. Observational studies conducted in real-world settings have further examined long-term adherence and monitored outcomes reflecting daily functioning over extended periods.

Evidence for Primary Generalized Tonic-Clonic Seizures

Research exploring the use of Файкомпа for primary generalized tonic-clonic seizures (PGTCS) is centered around one major Phase III RCT. Research examined the medicine as an add-on therapy, primarily in adults and adolescents whose PGTCS were studied in the context of Idiopathic Generalized Epilepsy (IGE). The main goal monitored was the measured difference in PGTCS frequency compared to placebo.

Gaps and Uncertainties in the Research

While evidence is extensive for adjunctive use, limitations exist. The pivotal studies primarily focused on populations with drug-resistant epilepsy, and the core double-blind treatment phases typically had limited follow-up durations (around 19 weeks). Data for certain groups, such as those newly diagnosed or the full spectrum of pediatric populations, remain insufficient. The evidence supporting monotherapy was primarily extrapolated from trials originally designed for add-on use, meaning dedicated monotherapy RCTs are lacking.

Common questions about Файкомпа (FAQ)

Q: How does Файкомпа compare to older epilepsy medications?

A: Official documents classify this medicine as a first-in-class treatment because it has a unique mechanism of action, working as an AMPA receptor antagonist. Due to this unique pharmacological profile, official guidelines indicate that it generally does not require routine monitoring of blood counts or liver function tests, unlike some older antiepileptic drugs.

Q: How long does it usually take to notice any effect from Файкомпа?

A: The medicine is administered via a gradual dose adjustment. It is subject to a required dose-titration, where the amount is gradually adjusted in increments, typically no more frequently than weekly, until a stable maintenance amount is defined. The drug's long half-life is noted in the official pharmacology sections, which informs this careful adjustment process.

Q: Do the side effects of Файкомпа usually go away over time?

A: Official patient counseling information notes that some side effects may occur when initiating treatment or when dose adjustments are made. These effects, which can include dizziness or sleepiness, are noted to potentially subside as the body adjusts to the medicine during the early phases of treatment.

Q: Can Файкомпа affect the effectiveness of birth control pills?

A: Official documentation indicates a potential effect. Regulatory information states that the medicine, particularly at a 12 mg dose, can reduce the effectiveness of hormonal contraceptives that contain levonorgestrel. Users of this type of hormonal contraceptive should be aware of this documented risk.

Q: What happens if a person suddenly stops taking Файкомпа?

A: Official regulatory warnings advise against abruptly stopping this medicine. Doing so may cause seizures to return or occur more often. Regulatory documents state that if the medicine is discontinued, gradual reduction is required to minimize this risk.

Q: Why is the drug described as a positive allosteric modulator of AMPA receptors?

A: The medicine is classified as a selective, non-competitive antagonist (a blocker) of the AMPA glutamate receptor. The mechanism is described in official documentation as functioning as a negative allosteric modulator at the receptor. This interaction reduces the flow of excitatory current in the brain.

Q: What happens if I forget to take a dose of Файкомпа?

A: Official patient information notes that if a dose is missed, the recommended action described in the label is to skip the missed dose and take the next scheduled dose at the usual time the following day. Taking an extra amount to make up for the missed one is advised against.

Q: Are there any foods or drinks to avoid while taking Файкомпа?

A: Official regulatory documents advise against the co-use of alcohol (ethanol) due to the potential for heightened central nervous system (CNS) depression, which can increase side effects like dizziness or sleepiness. The product label also notes the medicine may officially be taken with or without food.

Q: Is Файкомпа safe to use for children or teenagers?

A: The medicine has specific age approvals for different seizure types (e.g., 4 years and older). Regulatory documents include a special warning that certain psychiatric and behavioral reactions, such as aggression, may occur slightly more frequently in adolescents compared to adults. Close monitoring is documented as being required for these patient groups.

Q: What are the rules for driving or operating machinery while taking Файкомпа?

A: The official patient counseling documents contain a warning that users must not drive or operate complex machinery until they are certain how the medicine affects their alertness and coordination. This warning is due to the potential for dizziness, drowsiness, and coordination problems.

Q: Are there any long-term studies available for Файкомпа?

A: Regulatory applications reference completed extension studies that have followed some patients for durations exceeding one year. These studies have examined the medicine's use for extended periods to gather long-term safety data.

Q: Is Файкомпа known to cause dependence?

A: Yes. Regulatory agencies have classified the medicine as a Schedule III controlled substance. This classification is due to the drug’s documented potential for abuse and dependence.

Q: Why are there different strengths of the Файкомпа tablet available?

A: The medicine is available in various strengths, ranging from 2 mg to 12 mg. This range of tablet strengths is necessary to support the mandatory gradual dose-titration protocol that requires incremental dose adjustments to achieve a stable treatment amount.

Q: What is the difference between the immediate-release and extended-release versions of some epilepsy drugs, and does Файкомпа have both?

A: Official regulatory documents list the available forms as film-coated tablets and an oral suspension (liquid). There is no mention of a separate extended-release (ER) version in the official prescribing information for this medicine.

Q: Why do doctors have to monitor patients closely when starting Файкомпа?

A: Official regulatory guidelines mandate close monitoring for patients, especially during the initial titration phase and after any dose increase. This is primarily done because of the requirement to screen for serious psychiatric and behavioral side effects, such as aggression and hostility.

Q: What should I do if I experience a skin rash while taking Файкомпа?

A: Official patient counseling information states that users should contact a healthcare provider right away if they experience signs of a serious skin or systemic reaction. This warning applies if a rash is accompanied by other symptoms like fever, swollen lymph glands, or yellowing of the skin or eyes.

Q: Does Файкомпа require a special kind of prescription?

A: Yes. Due to its classification as a Schedule III controlled substance, the medicine is subject to special federal and state regulations. These regulations impose specific requirements on how the medicine is prescribed and dispensed.

Q: Is there an official patient medication guide for Файкомпа?

A: The official documentation indicates the availability of patient materials. Regulatory documents, such as the FDA Prescribing Information, include a dedicated section for Patient Counseling Information that outlines the key safety and usage facts for users.

Q: Does Файкомпа have any known effects on kidney function?

A: Clinical data reviewed by regulatory bodies indicated no clinically important effects on standard renal function tests, suggesting a low potential for direct kidney toxicity. Dosage adjustments are not required for people with mild kidney impairment.

Q: Is Файкомпа considered a first-line treatment for its approved conditions?

A: The medicine is officially approved for use as adjunctive therapy (or add-on treatment) for its listed seizure types. This means the drug is generally intended to be used in addition to other seizure medications, as opposed to being a primary, stand-alone treatment.

Q: What kind of specialist typically prescribes Файкомпа?

A: The use of the medicine, especially for initial authorization and ongoing management, often requires it to be prescribed by or in consultation with a neurologist or epilepsy specialist. This ensures that the treatment is aligned with expert guidance.

Q: Does Файкомпа have different names in other countries?

A: The medicine is marketed internationally under the trade name Fycompa across many different regions, including the United States, Europe, and Canada. The active substance in all regions is perampanel.

Q: Is Файкомпа used for types of seizures other than the ones listed in the main uses?

A: Official regulatory approval is limited to the treatment of partial-onset seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures. The official indications do not include other types of seizures.

How to Store and Dispose of Fycompa (Perampanel)

Fycompa must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Formulation	Temperature and Protection
Tablets & Suspension	Store at room temperature (up to 30 C or 86 F).
Tablets & Suspension	Must be kept in the original container and protected from light and moisture.
Oral Suspension	Once opened, the suspension must be used within 90 days.

Both forms must be stored out of the sight and reach of children.

Disposal Instructions

As a controlled substance, unused Fycompa should be disposed of through an authorized drug take-back program if available. Alternatively, mix the medication with an unappealing substance, place it in a sealed container, and discard it in the household trash. The product must not be disposed of via wastewater.